Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Will Accept Primary Mode Of Action Definition Comments Until Jan. 24

This article was originally published in The Gray Sheet

Executive Summary

Clarification of primary mode of action (PMOA) is a priority for the soon-to-be established Office of Combination Products, according to Mark Kramer, director of the agency's current combination product program within the FDA Office of the Ombudsman

You may also be interested in...



Primary Mode Of Action Definition Assessment In Progress – FDA

Stakeholders will have an opportunity to comment on FDA's planned interpretation of "primary mode of action," according to agency officials

Primary Mode Of Action Definition Assessment In Progress – FDA

Stakeholders will have an opportunity to comment on FDA's planned interpretation of "primary mode of action," according to agency officials

Baxter Urges OCP Review Panel For Jurisdictional Assignment

Consultative reviews for combination products should be linked to review division goals as an incentive for completing timely consults, American Medical Systems recommends

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017560

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel